HAART (>2 NRTIs and >1 PI) with recorded baseline and subsequent CD4 cell percentage and HIV-1 RNA results. Patients were placed in 3 classes according to CDC immunologic criteria and CD4 lymphocyte percentage at the time of HAART initiation [23] . Records were evaluated for age at initiation of HAART, duration of HAART, CD4 cell percentage, and HIV-1 load before and during HAART.
CD4 cell percentage. Blood samples obtained at the initiation of HAART and during follow-up visits were analyzed by flow cytometry for CD4 + CD3 + and CD8 + CD3 + cells by Epics-Profile II automated flow cytometer (Coulter). CD4 cell percentage response was determined on the basis of the change over time during HAART. Immunologic success was defined as a positive CD4 cell percentage slope, and failure was defined as a negative slope.
Plasma HIV-1 RNA levels. HIV-1 RNA copy numbers at baseline and during follow-up visits were assessed by reverse-transcriptase polymerase chain reaction (Amplicor; Hoffman-La Roche). The minimum level of detection was 400 HIV-1 RNA copies/mL for this technique or 50 HIV-1 RNA copies/mL by the ultrasensitive method. Undetectable virus load was reported as 399 HIV-1 RNA copies/mL and 49 HIV-1 RNA copies/mL, respectively. HIV-1 load response was determined on the basis of change over time during HAART.
Statistical analysis. Age at the start of HAART, the duration of HAART, CD4 cell percentage, and HIV-1 load (HIV-1 RNA copies/mL) were recorded. Results were analyzed on an intent-totreat basis. Linear regressions were performed on the CD4 cell percentage and HIV RNA data: we calculated the slopes and intercepts during HAART by using Sigma Stat 3.0 computer software (Jandel Scientific).Comparisonamonggroupswas donebyone-wayanalysis of variance (ANOVA). A normality test was performed for all regression procedures by use of the Kolmogorov-Smirnov test. If the normality test was passed and differences in mean values among groups were statistically significant (P , :05), then pairwise multiple comparisons were done by the Tukey test. If the normality test was not passed, Kruskal-Wallis ANOVA on ranks was done; if differences in the median values among groups were statistically significant (P , :05), pairwise multiple comparisons were done by the Dunn method. HIV-1 load and CD4 cell responses were determined by change over time during HAART. Virologic failure or success was defined by negative or positive regression slopes, respectively. Viral success and immunologic success between groups was determined by x 2 testing. Evaluation of thymic output was assessed by measuring T cell receptor (TCR) excision circles (TRECs) in peripheral blood mononuclear cells (PBMC) by a modification of the approach described by Zhang et al. [24] . Eight of our group of 85 children had multiple TREC measurements during HAART.
Viral phenotype. The presence of syncytium-inducing (SI) virus was determined in a cohort of 37 patients treated with HAART, as described elsewhere [25] . Whenever possible, all specimens were evaluated prospectively for the presence of SI virus. As described elsewhere, 10 6 freshly drawn PBMC were inoculated into 6-well plates containing cultures of MT-2 cell lines [26] . The assay was done on cells before starting HAART and every 3 months while receiving HAART for 12 months. Cultures were examined at days 5, 7, and 14 to look for syncytium formation. Assays were considered to be negative if no syncytia were observed by day 14 of culture. Of the 85 children in the study cohort, 37 had evaluable pre-and post-HAART results from serial MT-2 assays.
Results
Demographic characteristics of the study population. The 85 study children receiving HAART were stratified into 3 groups on the basis of their immunologic status at the time of the initiation of HAART, according to current CDC immunologic criteria [23] . There were 23 patients in group 1, 12 in group 2, and 50 in group 3. Table 1 shows baseline demographic characteristics.
Children in CDC category 1 tended to be younger than those in the other categories, although the difference was not statistically significant (P ¼ :093). The main reason for the age difference was the early initiation of HAART in the newborn period after HIV infection was confirmed while CD4 T lymphocytes were still preserved. Reanalysis after exclusion of children ,1 year old from each group resulted in data that were normally distributed (table 1) . Differences between ages (mean) were not statistically significant (P ¼ :971). The duration of HAART was shorter in children in CDC group 1 than in the other groups, although not statistically significant (table 2) . The difference in total duration of HAART also was not statistically significant when analysis was limited to children .1 year old. CD4 cell percentage response to HAART. Table 2 shows baseline CD4 cell percentage intercepts and slopes for each CDC group. The mean baseline CD4 cell percentage intercept in patients in CDC group 1 was 34.29%. During therapy, 9 (39.1%) of 23 children in CDC group 1 had an increase in CD4 cell percentage. The mean baseline CD4 cell percentage intercept in group 2 was 21.42%, and CD4 cell percentage increased in 7 (58.3%) of 12 patients on HAART. Among the children in CDC group 3, the baseline CD4 cell percentage intercept was 11.73%, and the CD4 cell percentage improved in 45 (90%) of 50 patients. This increase was statistically significant, compared with the other 2 groups (P , :001).
Regression analyses by group (table 2) suggested that CD4 cell percentage decreased in group 1, despite HAART. In CDC groups 2 and 3, the percentage increased with slopes of 0.057 and 0.3, respectively. This increase percentage was significantly greater in children in CDC group 3 (P , :001) than in the other 2 groups, even after excluding patients younger than 1 year. Figure 1 shows a comparison of CD4 cell percentage changes among CDC groups. Median regression lines defining CD4 cell percentage changes in CDC groups 2 and 3 had positive slopes, whereas the regression line in group 1 had a negative slope.
HIV-1 RNA response to HAART. Mean HIV-1 RNA copy (log 10 ) intercepts before the start of HAART did not differ significantly by group (P ¼ :154; table 2). Responses were determined on the basis of the virus load slope. In group 1, HIV load de- Regression analyses by groups showed that HIV-1 load had a tendency to decrease in groups 1 and 3, and the change was greater in group 1 than in group 3 (table 2). In group 2, virus load tended to increase during therapy. These differences were not statistically significant (P ¼ :154) and did not change after we reassessed those .1 year old. Figure 2 shows comparisons of HIV RNA changes among CDC groups.
Patients were further divided into 4 categories on the basis of concurrent virologic and immune responses (table 3): (1) responders had immunologic and viral success; (2) nonresponders had immunologic and viral failure; and (3) subjects with discordant results had immunologic failure and virologic success or (4) immunologic success and virologic failure. HIV-1 load and CD4 cell percentage responses were determined on the basis of the slope during HAART. Examples are shown in figure 3 . Discordant responses were statistically significantly different among the groups (P , :001; table 3). The differences between groups with immunologic success (with and without virologic success) and immunologic failure (with and without virologic success) also were statistically significant (P , :001).
TRECs in PBMC. Eight children receiving HAART had several TREC measurements during treatment with HAART (figure 4). They were divided into 3 groups, depending on their responses to HAART: virologic and immunologic success (3 patients), immunologic failure but virologic success (4 patients), and immunologic success but virologic failure (1 patient). In the patients with immunologic success, TREC levels increased over time, independently of the virologic response. In 1 child with immunologic failure but virologic success, TRECs stayed at baseline levels.
HIV-1 phenotype by SI assay. HIV-1 phenotype was followed for 1 year in 37 patients. Initially there were 20 patients with SI variants and 17 with non-SI (NSI) variants. HIV-1 SI variants were prevalent mainly in patients in CDC group 3 (table 4). During 1 year of HAART, 15 of 20 patients lost their SI variant. Of the 15 with a switch to NSI variants, HIV load decreased in 9 (60%) patients; 4 patients had undetectable levels. CD4 cell percentage increase was also observed in 13 (86.7%) of the 15 patients (table 4). All 5 patients with persistent SI HIV-1 phenotype had increased CD4 cell percentage; 4 children had virus load decreases. Of the 17 patients with NSI phenotype at baseline, 15 retained the NSI phenotype (6 with HIV decrease and 10 with CD4 cell percentage increase), and 2 patients who developed new SI variants had a CD4 cell percentage decrease and virus load increase.
Discussion
We believe that the present study is the first long-term follow-up of the effects of HAART in children with different stages of immunosuppression. Previous studies of HAART in children described mainly patients with severe or moderate immunosuppression who were followed for 16 weeks to 28 months [4] [5] [6] [7] [8] [9] [10] .
The effect of HAART on CD4 immunoreconstitution and HIV RNA load in children correlated with the results of previous studies [4] [5] [6] [7] [8] [9] [10] . Increases in CD4 cell percentage were seen in 39.1%, 58.3%, and 90% of patients in CDC groups 1-3, respectively. This was striking when HAART was instituted in CDC group 3 (CD4 cell percentage slope of 0.3 vs. 0.057 and 20.09 in groups 2 and 1, respectively; P , :001). Vigano et al. [5] also showed that CD4 cell increases were statistically greater in group 3 than in group 2 over a period of 18 months. In our experience, the median CD4 cell percentage decreased in patients in group 1 (even after adjusting for age) during HAART, although this was not statistically significant, compared with group 2. This could be explained partially by the anticipated normal decrease in CD4 cell percentage during the first 5 years of life, although most children in this group were .5 years old (range, 0.08-15.17 years) [27] . Exclusion of children ,1 year old did not change the results. A limitation of this study is its observational retrospective nature. In addition, we did not assess the roles of treatment adherence or HIV drug resistance. The effect of HAART on HIV-1 load in our group of children did not differ significantly on the basis of immunologic status at the time of initiation of HAART. Total virus suppression by current methods of detection was achieved in 34.8%, 25%, and 32% of patients in CDC immunologic groups 1-3, respectively. The response was lower than that in other studies with shorter periods of observation: 51% by Sleasman et al. [7] and 72% and 87% in groups 3 and 2, respectively, in the study by Vigano et al. [5] .
Previous studies showed that children possess the potential to reconstitute CD4 cells, even when they have advanced disease and incomplete virus suppression [6, 7] . This was confirmed by our longer term observation. A number of patients (31%) exhibited discordant responses with immunologic improvement and virologic failure. Treatment strategies in this situation remain controversial and include options to continue, modify, or discontinue the existing regimen.
The effect of HAART on T cells was first demonstrated by Autran et al. [28] through 3-phase T cell reconstitution after HAART: early increase of memory CD4 cells, reduction in T cell activation and decline in CD8 cells, and late increase in naive CD4 cells. The increase in CD4 cell count could be further explained through either (or both) an increase in thymic output [24, [29] [30] [31] [32] or a decrease in the apoptosis of CD4 cells [9, 33] . Douek et al. [29] demonstrated an increase in thymic output during HAART through measurement of episomal DNA circles that are generated during excisional rearrangement of TCR genes (TRECs) [29] . In a study of 9 children, they found that thymic output (through TREC increases) was restored with HAART over 20 months, mainly in children with total virus suppression [30] . Zhang et al. [24] found increased TRECs during HAART-primarily in persons with existing thymic impairment [26] . Even though our TREC data are limited to 8 patients, increased thymic output in children with immunologic response, independent of virus load suppression, is consistent with longitudinal measurements in adults, as reported by Lecossier et al. [31] , and in children, as reported by Chavan et al. [32] .
HAART may impact HIV, despite incomplete suppression of viral replication, either by resulting in changes in the tropism [6, 34] or fitness of the virus [35, 36] . SI variants of HIV-1 (1 February) 295 [26] , T cell tropic viruses that use CX chemokine receptor 4 as a coreceptor for entry into CD4 cells [37] , are associated with accelerated T cell decline and rapid disease progression [38] [39] [40] [41] . In our study, HAART was associated with a switch to NSI variants in 15 of 20 patients with SI variants before therapy (of those, 11 had persistently high virus loads). Most of these patients (24 of 37) were in CDC group 3. This skewing of the data toward CDC group 3 may have biased our results, but the consistent switch of phenotype from SI to NSI is, in itself, a remarkable finding. Studies in adults have shown sustained CD4 cell response after virologic failure, with slower decline of CD4 cells while receiving HAART than without treatment [42, 43] . In European observational studies, clinical progression during HAART was rare in adults with immunologic response, despite virologic failure [44, 45] . In our study, HAART had the greatest effect on immune reconstitution when started in patients with the greatest immunosuppression. The effect on virus load was similar among the groups, as described elsewhere for adults [46] . These observations raise doubt of the need to start potent antiretroviral therapy in asymptomatic HIV infection when significant viremia is used as the only decision criterion [12, 47] . Arguments favoring early initiation of HAART include evidence that early HAART prevents loss of immune function and that early suppression of viral replication prevents development of mutant variants [48] [49] [50] [51] . In vertically HIV-1-infected infants, evidence is accumulating for the benefits of starting HAART early in the newborn period-immediately after confirming HIV-1 infection [10] . Early combination antiretroviral therapy has led to a significant reduction of plasma viremia, preservation of peripheral blood CD4 T cells after the suppression of viral replication, and normal growth and development in such children [10] . Infants with intrauterine HIV-1 infection with thymic dysfunction were more likely to have disease progression and higher mortality [52] .
There may also be reasons to delay therapy until progression to more advanced disease. HAART does not cure HIV infection [53, 54] . Furthermore, evaluation of immune function in adults receiving HAART has demonstrated restoration of CD4 cell function in most patients, including those with moderate or severe CD4 cell suppression, in vitro by use of lymphocyte proliferation assay and in vivo by use of delayed-type hypersensitivity assay to recall antigens and immunization [55] [56] [57] [58] [59] . This has been confirmed in children [5, 6] , although reconstitution was more likely to be achieved in children with less advanced disease [5] . In Pediatric AIDS Clinical Trials Group study 338, which included immunologically stable children (CDC groups 1 and 2), lymphocyte proliferation responses to candida, tetanus, and HIV antigens (p24/25/gag and rgp120) did not improve significantly over 48 weeks when the children were receiving PI-containing regimens [9] .
Our results support the delay of HAART for asymptomatic HIV infection until more advanced stages (immunological or clinical) of the disease occur [60, 61] . Additional long-term clinical studies are needed to adequately assess the safety of delaying early HIV-1 treatment with HAART in children. Such studies should assess, in particular, the risk of central nervous system HIV infection and the clinical use of markers of disease progression in addition to or in lieu of HIV titer in children.
